PULM

Rating neutralTentativeAI MemoPost-earnings T+3

Pulmatrix

As of 2026-05-16/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Eos merger closing remains the key near-term value gate • 2026-09-30

Expected move: -14%

Biggest risk

The bear case is that Pulmatrix has effectively paused internal clinical advancement, depends on a merger it does not fully control, and disclosed substantial doubt about continuing as a going concern over the next year without that closing. If the merger breaks, financing, liquidation, or severely dilutive alternatives could dominate the equity outcome [#10-Q-2026-05-15].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The bull case is no longer about near-term operating acceleration; it is that the Eos merger closes on schedule, resolves the immediate going-concern overhang, and leaves current holders with a stake in a better-capitalized combined company while standalone Pulmatrix assets retain monetization optionality [#10-Q-2026-05-15].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-16

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Asset monetization remains the main standalone upside outside the merger
Cipla-led PUR1900 Phase 3 start in India is a real but lower-visibility external option
The bull case is no longer about near-term operating acceleration; it is that the Eos merger closes on schedule, resolves the immediate going-concern overhang, and leaves current holders with a stake in a better-capitalized combined company while standalone Pulmatrix assets retain monetization optionality [#10-Q-2026-05-15].

BearKey bullets

All U.S.
clinical development is currently on hold while the company seeks to license or monetize assets, limiting organic operating catalysts [#10-Q-2026-05-15] [#8-K-2026-05-15].
Coverage is thin and liquidity is likely fragile, so price action can disconnect from fundamentals around filings and corporate updates.

WatchKey bullets

Eos merger closing remains the key near-term value gate

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $1 (p=45%)

Bull/Bear spread: +44% / -71%

Vs latest close: Bull +44% · Base -14% · Bear -71%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

The post-earnings filing set materially confirmed the thesis change, but the tone remains monitoring-oriented rather than bullish. The May 15 8-K and Q1 release mainly reiterated the Eos merger, the $1.0 million preferred financing already tied to that deal, and a limited cash bridge rather than showing renewed internal program momentum [#8-K-2026-05-15]. No reliable analyst revision or target-change set was available in the evidence packet after the print, and with only the May 15 anchor price of $1.25 in the packet, the immediate market-reaction read-through remains limited. Net result: evidence is usable but tentative because the stock is still primarily a merger-and-runway situation.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Asset monetization remains the main standalone upside outside the merger
Cipla-led PUR1900 Phase 3 start in India is a real but lower-visibility external option

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-05-29

Nearest Scenario: Base (∆ 14%)

Targets vs latest close: Bull +44% · Base -14% · Bear -71%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Eos merger closing remains the key near-term value gate
Pulmatrix said the proposed merger with Eos SENOLYTIX is anticipated to close in the third quarter of 2026, subject to customary closing conditions. The 10-Q says future operations are highly dependent on the merger's success; if it fails, the company may need to pursue other strategic alternatives or liquidation. The same filing says Pulmatrix stockholders are expected to own about 6% of the combined company on a fully diluted basis, while concurrent financings total $19 million in aggregate gross proceeds including $1.0 million invested in Pulmatrix [#10-Q-2026-05-15] [#8-K-2026-05-15].
Prob 55.00% • Move 35.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Asset monetization remains the main standalone upside outside the merger
2026-12-31
Management said all U.S. clinical development is currently on hold while Pulmatrix works to license or monetize its clinical assets. PUR3100 remains Phase 2-ready with prior FDA IND acceptance, while PUR1800 and the iSPERSE platform are also being positioned for partnering or monetization; any transaction would matter disproportionately at the current micro-cap equity value, but timing and counterparties remain uncertain [#10-Q-2026-05-15] [#8-K-2026-05-15].
Prob 35% • Move 70% • Priced-in 25%
Cipla-led PUR1900 Phase 3 start in India is a real but lower-visibility external option
2026-12-31
Pulmatrix said partner Cipla completed a Phase 2 study in India, published positive results, and received approval from India's regulator to proceed to a Phase 3 trial that Cipla expects to commence in 2026. Pulmatrix would receive 2% royalties on future ex-U.S. net sales, so a trial start would help validate residual platform value, but it is partner-controlled and likely secondary to the merger thesis [#8-K-2026-05-15].
Prob 30% • Move 20% • Priced-in 40%

Risks

All U.S. clinical development is currently on hold while the company seeks to license or monetize assets, limiting organic operating catalysts [#10-Q-2026-05-15] [#8-K-2026-05-15].
Coverage is thin and liquidity is likely fragile, so price action can disconnect from fundamentals around filings and corporate updates.
Current Pulmatrix stockholders are expected to own only about 6% of the combined company on a fully diluted basis, limiting upside participation if the merger closes [#10-Q-2026-05-15].
Management disclosed substantial doubt about the company's ability to continue as a going concern beyond one year without the merger closing [#10-Q-2026-05-15].
Merger execution risk is the central issue; the 10-Q says future operations are highly dependent on successfully consummating the Eos merger [#10-Q-2026-05-15].

Peers

Symbol	Summary
MBIO	Loose micro-cap biotech comparator with event-driven financing sensitivity; useful for framing how binary corporate actions can dominate fundamental program value.
RVPH	Small-cap clinical biotech with milestone and capital-markets dependence; relevant mainly as an event-volatility and runway comparator rather than a therapeutic peer.
ENVB	Micro-cap biotech with thin coverage and high execution risk; helpful as a comparator for sentiment fragility when strategic or funding updates outweigh operating progress.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16

AI Stock Memo: PULM - Pulmatrix - RankAlpha